Lexaria Bioscience’s (LEXX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lexaria Bioscience (NASDAQ:LEXX) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Lexaria Bioscience’s Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($8.00) EPS and FY2025 earnings at ($0.31) EPS.

Lexaria Bioscience Stock Down 1.9 %

Shares of Lexaria Bioscience stock opened at $2.09 on Monday. Lexaria Bioscience has a 52 week low of $1.20 and a 52 week high of $6.85. The firm’s 50 day moving average is $2.67 and its two-hundred day moving average is $3.00. The firm has a market capitalization of $33.06 million, a P/E ratio of -4.82 and a beta of 1.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. HighTower Advisors LLC acquired a new stake in Lexaria Bioscience in the third quarter valued at $40,000. XTX Topco Ltd lifted its stake in shares of Lexaria Bioscience by 47.8% in the third quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after purchasing an additional 6,024 shares during the period. Renaissance Technologies LLC purchased a new stake in Lexaria Bioscience during the second quarter worth about $63,000. Geode Capital Management LLC grew its position in Lexaria Bioscience by 31.0% during the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock worth $459,000 after buying an additional 35,608 shares during the period. Finally, Armistice Capital LLC purchased a new position in Lexaria Bioscience in the second quarter valued at about $2,836,000. 13.06% of the stock is currently owned by institutional investors and hedge funds.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.